QNCX

Quince Therapeutics Inc
0.97
-0.0094 (-0.96%)
Company Name Stock Ticker Symbol Market Type
Quince Therapeutics Inc QNCX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0094 -0.96% 0.97 04:00:05
Open Price Low Price High Price Close Price Prev Close
0.9794
more quote information »

Recent News

Date Time Source Heading
2/02/202318:38EDGARStatement of Changes in Beneficial Ownership (4)
2/02/202318:36EDGARStatement of Changes in Beneficial Ownership (4)
2/02/202318:33EDGARStatement of Changes in Beneficial Ownership (4)
2/02/202318:30EDGARStatement of Changes in Beneficial Ownership (4)
1/30/202316:05BWQuince Therapeutics Provides Pipeline Update and Business..
1/27/202308:00BWQuince Therapeutics Completes the Sale of Legacy Protease..
12/16/202216:04EDGARCurrent Report Filing (8-k)
12/07/202217:38EDGARStatement of Changes in Beneficial Ownership (4)
11/09/202216:26EDGARQuarterly Report (10-q)
9/16/202208:00BWQuince Therapeutics Presents Preclinical Data at MHSRS 2022..
9/12/202208:00BWQuince Therapeutics Presents Preclinical Data at ASBMR 2022..
9/08/202217:59EDGARStatement of Changes in Beneficial Ownership (4)
8/30/202216:05BWQuince Therapeutics Presents Preclinical Data at OI 2022..
8/25/202216:05BWQuince Therapeutics to Present at Upcoming Scientific..
8/09/202216:28EDGARQuarterly Report (10-q)
8/04/202208:00BWQuince Therapeutics to Present at Canaccord Genuity 42nd..
8/01/202209:17EDGARCurrent Report Filing (8-k)
7/27/202208:01BWCortexyme Corporate Name Change to Quince Therapeutics to..
7/27/202208:00BWCortexyme Successfully Completes Phase 1 Single and Multiple..
7/22/202216:26EDGARCurrent Report Filing (8-k)
7/08/202212:57EDGARSchedule 13g
(sc 13g/a)
7/01/202217:03EDGARStatement of Changes in Beneficial Ownership (4)
6/21/202208:00BWCortexyme Announces Preclinical Data Demonstrating Efficacy..
6/13/202208:00BWCortexyme Appoints June Bray to its Board of Directors
6/10/202217:02EDGARCurrent Report Filing (8-k)
6/08/202216:14EDGARStatement of Changes in Beneficial Ownership (4)
6/08/202216:11EDGARStatement of Changes in Beneficial Ownership (4)
6/08/202216:10EDGARStatement of Changes in Beneficial Ownership (4)
5/27/202218:17EDGARAmended Statement of Changes in Beneficial Ownership (4/a)
5/25/202216:09EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
5/20/202216:08EDGARSecurities Registration: Employee Benefit Plan (s-8)
5/20/202208:16EDGARCurrent Report Filing (8-k)
5/20/202208:01BWCortexyme Appoints Dr. Philip Low to Its Board of Directors
5/20/202208:00BWCortexyme Successfully Completes Acquisition of Novosteo
5/19/202216:46EDGARProspectus Filed Pursuant to Rule 424(b)(5) (424b5)
5/18/202206:08EDGARNotice of Effectiveness (effect)
5/17/202206:06EDGARPost-effective Amendment Filed Solely to Add Exhibits to a..
5/12/202217:13EDGARCurrent Report Filing (8-k)
5/12/202208:00BWCortexyme to Participate at 4th International Conference on..
5/11/202212:45TRMNCredit Suisse Reaffirms Their Sell Rating on Cortexyme..
5/10/202208:09EDGARCurrent Report Filing (8-k)
5/10/202208:00BWCortexyme Announces Agreement to Acquire Novosteo
4/27/202216:04EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
4/27/202216:04EDGARProxy Statement (definitive) (def 14a)
3/22/202206:26TRMNCortexyme (CRTX) Gets a Buy Rating from H.C. Wainwright
3/21/202208:00BWCortexyme Provides New GAIN Trial Data at AD/PD 2022..
3/16/202218:34EDGARStatement of Changes in Beneficial Ownership (4)
3/16/202218:30EDGARInitial Statement of Beneficial Ownership (3)
3/15/202208:00BWCortexyme Appoints Marwan Sabbagh, MD, to its Board of..
3/14/202208:00BWCortexyme to Present New GAIN Trial Data at AD/PD 2022